Compare Affirm Holdings Inc (AFRM) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs Charles River Laboratories Intl. Inc — how do they compare? Affirm Holdings Inc trades at $74.5 (market cap $25.69B), while Charles River Laboratories Intl. Inc trades at $284.32 (market cap $13.46B). The key difference: Affirm Holdings Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Affirm Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | CRL | |
|---|---|---|
Market Cap | $25.69B | $13.46B |
Sector | Financials | Health |
52-Week High | $92.18 | $282.00 |
52-Week Low | $42.53 | $145.57 |
Enterprise Value | $32.30B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $75.54, up 0.39% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $3.22B in 2025, turning profitable with $52M net income. The stock faces resistance near $76-$78, while analyst consensus targets $96.40, implying 28% upside. Recent news highlights strong growth prospects and institutional interest.
Outlook is positive given accelerating revenue growth, expanding margins, and dominant buy-side analyst support. Key risks include high valuation multiples (P/E 69.7) and sensitivity to interest rate changes, but robust cash flow generation and market share gains support long-term upside.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
